Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138504

Published: 2020

Journal Articles

Next-Generation Sequencing in Non- BCR-ABL Mechanisms Resistance in Patients with Chronic Myeloid Leukemia: Results of a Pilot Study

Ilya Buldakov, Sergey Voloshin, MD PhD, Mikhail Fominykh, MD, Vasily Shuvaev, MD, Sergey Petrov, Alexander Chechetkin, MD PhD, Irina Martynkevich, MD PhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-142391

Published: 2020

Journal Articles

Next-Generation Sequencing Targeted Chronic Lymphocytic Leukemia Panel: A Pilot Study

Mariia Mikhaleva, MD, Irina Martynkevich, MD PhD, Sergey Petrov, Ilya Buldakov, Alexey Kuvshinov, MD, Vasily Shuvaev, MD, Alexander Chechetkin, MD PhD, Sergey Voloshin, MD PhD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-139418

Published: 2020

Journal Articles

The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Sergey Linnikov, Irina Martynkevich, MD PhD, Alexey Kuvshinov, MD, Anastasiya Kuzyaeva, Zhanna Chubukina, Vasily Shuvaev, MD, Elizaveta Kleina, Marina Bakai, Alexander Sсhmidt

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-139239

Published: 2020

Journal Articles

The Comparison of Results of Autologous Transplantation Using Non-Cryopreserved and Cryopreserved Hematopoietic Stem Cells (HSC)

Sergei Voloshin, MD PhD, Andrey Garifullin, MD, Sergey Linnikov, Anastasiya Kuzyaeva, Vasily Shuvaev, MD, Valentina Balashova, Georgiy Rysev, MD, Alexander Chechetkin, MD PhD, Zanna Chebukina

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142279

Published: 2020

Journal Articles

Immune Thrombocytopenia Associated with COVID-19 - Case Series

Ramil Fatkhullin, MD, Vasily Shuvaev, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142611

Published: 2020

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

Short-Term Noncryopreserved Hematopoietic Stem Cells: Single Center Experience of Autologous Transplantation

Sergei Voloshin, MD PhD, Andrey Garifullin, MD, Anastasiya Kuzyaeva, Vasily Shuvaev, MD, Alexander Schmidt, Alexey Kuvshinov, MD, Valentina Balashova, Zhanna Chubukina, Elena Belyakova, MD, Georgiy Rysev, MD, Alexander Chechetkin, Viktor Rugal'

Blood (2019) 134 (Supplement_1): 5636.

https://doi.org/10.1182/blood-2019-131695

Published: 2019

Journal Articles

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alexander Chechetkin, Stanislav Bessmeltcev, Anastasiya Kuzyaeva, Alexander Sсhmidt, Alexey Kuvshinov, MD, Irina Pavlova

Blood (2019) 134 (Supplement_1): 5593.

https://doi.org/10.1182/blood-2019-130092

Published: 2019

Journal Articles

Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia Who Achieved MRD-Positive Remissions after Induction Therapy

Alexey Kuvshinov, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Elena Belyakova, MD, Mariia Mikhaleva, MD, Andrey Garifullin, MD, Georgiy Rysev, MD, Alexander Bogdanov, MD PhD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alena Samorodova, MD, Iuliia Ruzhenkova, Iuliia Vokueva, Alexander Chechetkin

Blood (2019) 134 (Supplement_1): 5475.

https://doi.org/10.1182/blood-2019-129995

Published: 2019

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

Vasily Shuvaev, MD, Olga Vinogradova, MD PhD, Irina Martynkevich, MD PhD, Novitskaya Natalya, MD, Mikhail Fominykh, MD, Svetlana Tsareva, Dzhariyat Shikhbabaeva, Maria Pankrashkina, Mikhail Chernikov, Nikolay Sharkunov, MD PhD, Irina Zotova, MD, Vera Udaleva, MD PhD, Ekaterina Motyko, MD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5446.

https://doi.org/10.1182/blood-2018-99-114164

Published: 2018

Journal Articles

Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

Elizaveta Efremova, MD, Olesya Matvienko, MD, Natalya Korsakova, Mikhail Fominykh, MD, Natalya Silina, Ludmila Papayan, Lyubov Polushkina, MD, Ekaterina Motyko, MD, Irina Martynkevich, MD PhD, Vasily Shuvaev, MD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2018-99-118801

Published: 2018

Journal Articles

Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice

Vasily Shuvaev, MD, Karina Krutikova, MD, Svetlana Menshakova, MD, Natalya Kalinova, MD, Irina Martynkevich, MD PhD, Lyubov Polushkina, MD, Elena Belyakova, MD, Yury Krivolapov, MD PhD, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2018-99-114885

Published: 2018

Journal Articles

The Prognostic Significance of Minimal Residual Disease and Possibility of Its Correction in Multiple Myeloma

Andrey Garifullin, MD, Sergei Voloshin, MD PhD, Alexey Kuvshinov, MD PhD, Anastasiya Kuzyaeva, Alexander Sсhmidt, Zhanna Chubukina, Vasily Shuvaev, MD, Evgeniy Krasnikov, Sergey Linnikov

Blood (2018) 132 (Supplement 1): 5751.

https://doi.org/10.1182/blood-2018-99-118457

Published: 2018

Journal Articles

Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma

Mariia Mikhaleva, MD, Alexey Kuvshinov, MD PhD, Alexander Schmidt, Vasily Shuvaev, MD, Karina Krutikova, MD, Elena Belyakova, Irina Martynkevich, MD PhD, Alexander Chechetkin, Sergei Voloshin, MD PhD

Blood (2018) 132 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2018-99-119761

Published: 2018

Journal Articles

The Strategy of the Management of Patients with Chronic Lymphocytic Leukemia in the Post-Induction Period Based on the Results of the Evaluation of Minimal Residual Disease

Alexey Kuvshinov, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD PhD

Blood (2017) 130 (Supplement 1): 1732.

https://doi.org/10.1182/blood.V130.Suppl_1.1732.1732

Published: 2017

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

Journal Articles

The Significance of Flow Cytometry and Positron Emission Tomography and Computed Tomography (PET-CT) in the Assessment of the Minimum Residual Disease in Patients with Multiple Myeloma

Andrey Garifullin, Sergei Voloshin, MD PhD, Alexey Kuvshinov, MD, Alexander Schmidt, Vasily Shuvaev, MD PhD, Yuriy Kryvolapov, Elena Belyakova, Evgeniy Krasnikov, Alexander Chechetkin

Blood (2017) 130 (Supplement 1): 3097.

https://doi.org/10.1182/blood.V130.Suppl_1.3097.3097

Published: 2017

Journal Articles

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Natalia Lazorko, MD, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Irina Martynkevich, Mikhail Fominykh, MD, Anna Silyutina, MD, Katerina Ovsiannikova, Nadia Siordia, MD, Andrey Zaritskey, Elena Machulaytene, MD

Blood (2017) 130 (Supplement 1): 5255.

https://doi.org/10.1182/blood.V130.Suppl_1.5255.5255

Published: 2017

NARROW

Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry

Next-Generation Sequencing in Non- BCR-ABL Mechanisms Resistance in Patients with Chronic Myeloid Leukemia: Results of a Pilot Study

Next-Generation Sequencing Targeted Chronic Lymphocytic Leukemia Panel: A Pilot Study

The Prognostic Significance of Minimal Residual Disease in Multiple Myeloma in the Molecular Genetic Groups Msmart 3.0

The Comparison of Results of Autologous Transplantation Using Non-Cryopreserved and Cryopreserved Hematopoietic Stem Cells (HSC)

Immune Thrombocytopenia Associated with COVID-19 - Case Series

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Short-Term Noncryopreserved Hematopoietic Stem Cells: Single Center Experience of Autologous Transplantation

Significance of Modified Risk Stratification Msmart 3.0 and Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia Who Achieved MRD-Positive Remissions after Induction Therapy

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Russian Experience of Bosutinib Use in Chronic Myeloid Leukemia Patients in Routine Clinical Practice

Role of Molecular Drivers in Coagulation By Integral Assessment in Primary Myelofibrosis Patients

Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice

The Prognostic Significance of Minimal Residual Disease and Possibility of Its Correction in Multiple Myeloma

Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma

The Strategy of the Management of Patients with Chronic Lymphocytic Leukemia in the Post-Induction Period Based on the Results of the Evaluation of Minimal Residual Disease

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

The Significance of Flow Cytometry and Positron Emission Tomography and Computed Tomography (PET-CT) in the Assessment of the Minimum Residual Disease in Patients with Multiple Myeloma

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only